UCB to build new manufacturing capacity for Cimzia
The company said that the new manufacturing unit is expected to be operational in 2015 and requires an investment of EUR250m in two steps. UCB Technical Operations &
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.